POKONZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POKONZA (POKONZA).
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
| Metabolism | Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP3A4, to inactive metabolites. Also undergoes glucuronidation and excretion in bile and feces. |
| Excretion | Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20% |
| Half-life | Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days |
| Protein binding | 98% bound primarily to albumin and alpha-1 acid glycoprotein |
| Volume of Distribution | 0.5-0.8 L/kg; indicates moderate tissue distribution without extensive accumulation |
| Bioavailability | Oral: 85-95% (high first-pass metabolism partially saturable); Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes |
| Duration of Action | 12-24 hours; allows once-daily dosing; extended release formulations may provide 24-hour coverage |
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or hemodialysis. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 0.075 mg/kg every 8 hours. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years of age. |
| Geriatric use | No specific dose adjustment recommended; however, monitor renal function due to age-related decline, as tolerability may be reduced in patients ≥65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POKONZA (POKONZA).
| Breastfeeding | POKONZA is excreted in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, including nephrotoxicity and hepatotoxicity, breastfeeding is contraindicated during therapy and for 30 days after last dose. |
| Teratogenic Risk | POKONZA is a Category X drug. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal failure. Contraindicated in pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ponazuril or any component of the formulation","Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine)","Severe hepatic impairment"]
| Precautions | ["Use with caution in patients with hepatic impairment","May cause QT interval prolongation; monitor ECG in patients with cardiac disease or electrolyte abnormalities","Potential for drug interactions with CYP3A4 inhibitors and inducers","Not recommended for use in pregnant or nursing women due to lack of safety data"] |
Loading safety data…
| Fetal Monitoring |
| Maternal: baseline hepatic and renal function tests, complete blood count, and ECG; monitor for hypertension, proteinuria, and signs of preeclampsia. Fetal: serial ultrasound for growth, amniotic fluid volume, and anatomy; fetal echocardiography if cardiac abnormalities suspected. Perform nonstress test or biophysical profile weekly from 32 weeks. |
| Fertility Effects | POKONZA may impair fertility in females by causing ovarian failure and premature menopause; reversible in some cases. In males, may cause oligospermia or azoospermia, potentially irreversible. Advise fertility preservation prior to treatment. |